Genetically Modified Stem Cells and Irinotecan Hydrochloride in Treating Patients With Recurrent High-Grade Gliomas
Status:
Withdrawn
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
This phase I trial studies the side effects and best dose of genetically modified stem cells
when given together with irinotecan hydrochloride in treating patients with recurrent
high-grade gliomas. Irinotecan hydrochloride may stop the growth of tumor cells by blocking
some of the enzymes needed for cell growth. Placing a gene that has been created in the
laboratory into neural stem cells and injecting it into the brain may help irinotecan
hydrochloride kill more tumor cells once it reaches the brain.